-
公开(公告)号：US20250000958A1
公开(公告)日：2025-01-02
申请号：US18764576
申请日：2024-07-05
Applicant: CEDARS-SINAI MEDICAL CENTER
Inventor： Stanley Jordan , Jua Choi , Ashley A. Vo
Abstract: Described herein are methods for improving kidney function in subjects that have undergone kidney transplant. An effective amount of one or more complement component 1 esterase inhibitors is administered to the subject, resulting in long-term improvement on kidney allograft function.
-
公开(公告)号：US20170174760A1
公开(公告)日：2017-06-22
申请号：US15448406
申请日：2017-03-02
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley C. Jordan , Ashley Vo , Jua Choi
IPC: C07K16/24 , C07K16/28 , C07K16/00 , A61K39/395
CPC classification number: C07K16/00 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2866 , C07K16/2887 , C07K2317/24 , C07K2317/76
Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).
-
公开(公告)号：US20200207864A1
公开(公告)日：2020-07-02
申请号：US15779711
申请日：2016-12-09
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley Jordan , Ashley Vo , Jua Choi
Abstract: Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.
-
4.发明申请公开(公告)号：US20170022280A1
公开(公告)日：2017-01-26
申请号：US15219121
申请日：2016-07-25
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley C. Jordan , Ashley Vo , Jua Choi
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).
Abstract translation: 本文描述了使用IL-6抑制剂治疗移植器官的抗体介导的排斥反应的方法。 在一个实施方案中，IL-6抑制剂是替瑞珠单抗，并且与静脉内免疫球蛋白（IVIG）同时或依次施用。
-
公开(公告)号：US12059456B2
公开(公告)日：2024-08-13
申请号：US16646539
申请日：2018-09-14
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley Jordan , Jua Choi , Ashley Vo
CPC classification number: A61K38/57 , A61K9/0019
Abstract: Described herein are methods for improving kidney function in subjects that have undergone kidney transplant. An effective amount of one or more complement component 1 esterase inhibitors is administered to the subject, resulting in long-term improvement on kidney allograft function.
-
Patent Agency Ranking
公开(公告)号：US20220098317A1
公开(公告)日：2022-03-31
申请号：US17498278
申请日：2021-10-11
Applicant: CEDARS-SINAI MEDICAL CENTER
Inventor： Stanley Jordan , Ashley Vo , Jua Choi
Abstract: Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.
-
公开(公告)号：US20240218072A1
公开(公告)日：2024-07-04
申请号：US18386537
申请日：2023-11-02
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley Jordan , Ashley Vo , Jua Choi
CPC classification number: C07K16/2887 , A61P13/12 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/732
Abstract: Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.
-
公开(公告)号：US11865175B1
公开(公告)日：2024-01-09
申请号：US15967034
申请日：2018-04-30
Applicant: Cedars-Sinai Medical Center
Inventor： Stanley Jordan , Ashley Vo , Jua Choi
IPC: A61K39/395 , A61P37/06 , C07K14/705 , A61K38/17 , A61K39/00
CPC classification number: A61K39/39541 , A61K38/1774 , A61K39/3955 , A61P37/06 , C07K14/705 , A61K2039/505 , A61K2039/545 , A61K2300/00
Abstract: Provided herein are methods for treating, inhibiting, reducing the likelihood of and/or reducing the severity of antibody-mediated rejection (ABMR) in a subject with organ transplantation, by selecting a subject that has undergone an organ transplant; and administering to the subject a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent to the subject after transplantation, or both before and after transplantation.
-
公开(公告)号：US11840576B2
公开(公告)日：2023-12-12
申请号：US17498278
申请日：2021-10-11
Applicant: CEDARS-SINAI MEDICAL CENTER
Inventor： Stanley Jordan , Ashley Vo , Jua Choi
CPC classification number: C07K16/2887 , A61P13/12 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/732
Abstract: Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.
-
公开(公告)号：US20220265786A1
公开(公告)日：2022-08-25
申请号：US17633067
申请日：2020-08-07
Applicant: CEDARS-SINAI MEDICAL CENTER
Inventor： Stanley Jordan , Jua Choi , Ashley A. Vo , Edmund Huang
Abstract: Described herein are methods for improving long-term allograft survival and long-term kidney function in subjects that have undergone kidney transplant. An effective amount of one or more complement component 1 esterase inhibitors is administered to the subject, resulting in long-term improvement on kidney allograft survival and function.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.015 seconds)
